Skip to main content

Table 3 Analysis of potential risk factors for unfavorable DTC evolution in acromegalic patients classified according to stage, initial recurrence risk, initial and follow-up response

From: Acromegaly and thyroid cancer: analysis of evolution in a series of patients

Potential risks factors for unfavorable DTC evolution Age at diagnosis of DTC (years) Median (range) IGF-1 at diagnosis of DTC (ULN)
Median (range)
Time between DTC diagnosis and acromegaly control (years)
Median (range)
Insulin resistance
n (%)
Stage
(n = 24)
1 (n = 19) 1.19 (0.32–4.8) 0.83 (0–7) 8 (42.1)
2 (n = 4)   1.52 (1.32–1.70) 2.25 (1–3.6) 1 (25)
4b (n = 1)   2.31 0 0
p-value 0.55 0.36 1
Initial recurrence risk
(n = 24)
Low (n = 21) 51.5 (18–68) 1.44 (0.32–4.8) 1.25 (0–7) 8 (40)
Intermediate (n = 2) 55.5 (42–69) 0.97 (0.64–1.31) 2.13 (0.66–3.6) 0
High (n = 1) 66 2.31 0 0
p-value 0.33 0.33 0.69 0.68
Initial response
(n = 23)
Excellent (n = 12) 58.5 (18–69) 1.4 (0.32–3.09) 0.5 (0–7) 6 (50)
Indeterminate (n = 7) 50 (37–68) 1.34 (0.64–4.4) 0.83 (0–2.3) 3 (42.9)
Biochemical
incomplete (n = 3)
37 (37–38) 3.37 (1.94–4.8) 3 (0.25–4) 0
Structural
Incomplete (n = 1)
66 2.31 0 0
p-value 0.40 0.65 0.79 0.42
Response at the end of follow-up
(n = 23)
No evidence of disease (n = 19) 50 (18–69) 1.21 (0.32–4.4) 1 (0–7) 7 (36.8)
Indeterminate (n = 2) 65 (62–68) 1.8 (0.98–2.6) 1.8 (0–3.6) 1 (50)
Biochemical
incomplete (n = 1)
37 1.7 0 0
Structural
Incomplete (n = 1)
66 2.31 0 0
p-value 0.23 0.30 0.87 0.71
  1. DTC differentiated thyroid cancer, IGF-1 insulin-like growth factor type 1, ULN upper limit of normality